TrilliumBiO
- Company typePrivate
- Founded2022
- HeadquartersRockville, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
TrilliumBiO firmographics
Firmographics- Name
- TrilliumBiO
- Legal name
- Trillium Health, LLC
- Website
- https://trilliumbio.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
TrilliumBiO industry classification
Industry- Product category
- Diagnostic Laboratory Services
- NAICS
- Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
- akta.pro secondary industries
- Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Chemistry, Hematology & Coagulation Testing (Trial Support) (HLAGAEAE)
Keywords
Where TrilliumBiO is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TrilliumBiO business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Laboratory Diagnostic Testing Services: TrilliumBiO processes over 500,000 samples annually through its multi-accredited, CLIA-certified laboratory. Revenue is generated through diagnostic testing fees charged to healthcare providers, health systems, and pharmaceutical partners for validated assay services.
- Pharmaceutical and Biotech Partnership Services: The company collaborates with biotech and pharma partners to develop, validate, and commercialize companion diagnostic assays. These partnerships involve co-development, assay validation, and clinical laboratory services supporting partner therapeutic development programs and regulatory submissions.
- Companion Diagnostic Development and Licensing: TrilliumBiO develops and validates novel diagnostic tests in conjunction with biopharma partners, commercializing them as Laboratory Developed Tests (LDT) through its own laboratory infrastructure, generating licensing and development fees from partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | No-cost diagnostic test for aPAP (autoimmune Pulmonary Alveolar Proteinosis) |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
TrilliumBiO product offering
Product offeringCore offering
TrilliumBiO is a life sciences company that develops, validates, and commercializes diagnostic assays (Laboratory Developed Tests) through its multi-accredited, CLIA-certified, CAP-accredited, ISO 15189-accredited laboratory in Rockville, MD. It partners with biotech and pharmaceutical companies to co-develop companion diagnostics and provides biomarker discovery, assay validation, and clinical testing services to physicians and patients nationwide. Its portfolio includes specialized tests for autoimmune pulmonary alveolar proteinosis (aPAP ClearPath), alpha-1 antitrypsin deficiency (AlphaID), and uveal melanoma monitoring (Oncular), processing over 500,000 samples annually.
Product overview
TrilliumBiO is a biomarker discovery and translational diagnostics company operating a multi-accredited, CLIA-certified laboratory that has launched over 100 assays and processes over 500,000 samples annually. The company operates a platform-plus-services model offering a portfolio of specialized diagnostic tests including Oncular™ for uveal melanoma monitoring, AlphaID™ for alpha-1 antitrypsin deficiency screening, and aPAP ClearPath™ for autoimmune pulmonary alveolar proteinosis detection. Additional offerings include VEGF-D assay for LAM diagnosis, EMR integration workflows, and custom biomarker discovery services. The company collaborates with biopharma partners, academic medical centers, foundations, and patient advocacy groups to translate scientific discoveries into patient-ready diagnostics.
Differentiator
Problem solved
Functional benefit
Brands
- Oncular™: A uveal melanoma monitoring solution combining personalized digital PCR with cloud-based ctDNA analysis to track molecular residual disease, longitudinal ctDNA trends, and early molecular signals of treatment response or disease progression in metastatic uveal melanoma patients.
- AlphaID™
- aPAP ClearPath™
Products and services
- Oncular™ A Laboratory Developed Test for uveal melanoma monitoring that provides real-time, quantitative assessment of circulating tumor DNA (ctDNA) from a blood draw, delivering molecular residual disease status, longitudinal ctDNA trends, and early molecular signals of treatment response or disease progression using personalized digital PCR with cloud-based data analysis.
- AlphaID™ A diagnostic screening program for alpha-1 antitrypsin deficiency (AATD) that combines dried blood spot or buccal swab specimens with quantitative AAT serum measurement via immunoturbidimetry, detecting 14 clinically relevant SERPINA1 allelic variants including rare null alleles and compound heterozygotes missed by conventional testing.
- aPAP ClearPath™ A GM-CSF autoantibody blood test for diagnosis of autoimmune pulmonary alveolar proteinosis (aPAP), available as both a serum-based assay and a dried blood spot (DBS) test that requires only a finger-prick sample. Developed and processed in partnership with Savara Inc., offered as a no-cost diagnostic tool to patients.
- VEGF-D Assay A biomarker assay for lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, used for diagnosis and monitoring of LAM patients.
Quantifiable outcome
- GM-CSF autoantibody assay achieved 100% clinical accuracy in a cohort of 40 subjects (negative cohort n=20, positive cohort n=20)
- +4 more outcomes
Companies that use TrilliumBiO
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
TrilliumBiO technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
TrilliumBiO partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and supporting.
- OncobitcoreTrilliumBiO and Oncobit formed a strategic partnership to bring Oncobit's uveal melanoma monitoring solution to the United States. TrilliumBiO implements Oncobit's proprietary Personalized Monitoring (PM) platform, including cloud-based data interpretation software, to track circulating tumor DNA (ctDNA) dynamics in metastatic uveal melanoma patients. The partnership makes Oncobit's assay available nationwide through TrilliumBiO's multi-accredited laboratory, providing physicians with molecular residual disease information to support precise therapy decisions. In May 2026, the companies launched Oncular™ as the resulting product.
- BioHub Maryland (Maryland Tech Council)supportingTrilliumBiO joined BioHub Maryland, the workforce initiative powered by Maryland Tech Council, as an Elite Partner. This collaboration supports strengthening Maryland's life sciences ecosystem by highlighting career paths in laboratory medicine and expanding access to high-impact research and development opportunities. BioHub Maryland is a workforce initiative helping life sciences companies grow by showcasing career opportunities and providing access to talent and strategic resources.
- T-NeuroDxcoreTrilliumBiO and T-NeuroDx announced a strategic collaboration to advance the development and commercialization of blood-based biomarker diagnostics for Alzheimer's disease. The partnership combines TrilliumBiO's diagnostic assay development and clinical validation expertise with T-NeuroDx's biomarker science for Alzheimer's disease pathology. The companies aim to co-develop and validate blood-based biomarkers that can support earlier diagnosis, commercializing T-Neuro's technology as a Lab Developed Test (LDT). The initiative includes clinical studies across diverse populations to support regulatory submissions.
- Savara Inc.coreTrilliumBiO partnered with Savara Inc. as a CLIA-certified laboratory to develop and process the aPAP ClearPath GM-CSF autoantibody blood test for diagnosis of autoimmune pulmonary alveolar proteinosis (aPAP). The partnership developed both the serum-based assay and a dried blood spot (DBS) version using the ADX100 serum separator card. The test was offered as a simple, no-cost, noninvasive diagnostic tool to help confirm or rule out aPAP, addressing an estimated diagnosed prevalence of 7 cases per million in the US.
- Grifols Shared Service North AmericacoreTrilliumBiO collaborates with Grifols on the AlphaID screening program for alpha-1 antitrypsin deficiency. The partnership uses Grifols' FDA-cleared AAT genotyping assay (Progenika Biopharma, Spain), which detects 14 clinically relevant SERPINA1 allelic variants. TrilliumBiO provides dried blood spot and buccal swab specimen processing, quantitative AAT measurement via immunoturbidimetry, and nationwide testing logistics.
- Cincinnati Translational Pulmonary Science CentersupportingTrilliumBiO developed the dried blood spot GM-CSF autoantibody assay in collaboration with Savara Inc. and Cincinnati Translational Pulmonary Science Center. The study involved three independent analyses demonstrating robust analytical precision and strong correlations between serum from venipuncture and DBS samples.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
TrilliumBiO competitors and assessment
Company assessmentDirect peers
- NeoGenomics Laboratories: Specialty clinical laboratory focused on oncology-focused diagnostic testing and biomarker services for pharma partners. Closely comparable to TrilliumBiO in offering companion diagnostic development, clinical biomarker assays, and pharma services through a CLIA-certified lab.
- Natera: Molecular diagnostics company specializing in ctDNA-based MRD and oncology monitoring tests. Directly comparable to TrilliumBiO's Oncular™ MRD offering and its ctDNA-based molecular residual disease testing capabilities.
- Guardant Health: Liquid biopsy and ctDNA testing company with companion diagnostic partnerships. Comparable to TrilliumBiO in oncology molecular diagnostics and biopharma partnership models.
- BioReference Laboratories (OPKO Health): Full-service clinical diagnostics laboratory offering specialty testing across oncology, pulmonology, and rare diseases. Comparable to TrilliumBiO in multi-specialty LDT testing and biopharma partnership services.
- Myriad Genetics: Molecular diagnostics company developing companion diagnostics and hereditary disease tests. Comparable in offering proprietary biomarker tests commercialized through biopharma partnerships.
- Caris Life Sciences: Molecular diagnostics and precision medicine company offering comprehensive biomarker profiling and biopharma partnership services. Comparable to TrilliumBiO's companion diagnostic development platform.
- Veracyte: Genomic diagnostics company focused on specialty molecular tests for oncology and pulmonology. Comparable to TrilliumBiO's specialty test portfolio in pulmonology (aPAP, AATD) and oncology (Oncular).
Broad incumbents
- Laboratory Corporation of America (LabCorp): Large incumbent clinical laboratory network offering routine and specialty diagnostic testing nationwide. Comparable as a broad-scale US clinical lab competitor and potential commercial partner to TrilliumBiO.
- Quest Diagnostics: Largest US clinical laboratory offering routine and advanced diagnostics including rare disease and specialty testing. Comparable as a broad US lab incumbent that competes with TrilliumBiO for physician adoption and biopharma services contracts.
- Foundation Medicine (Roche): Specialty molecular diagnostics company offering comprehensive genomic profiling and biopharma companion diagnostic partnerships. Comparable in serving biopharma companion diagnostic development at scale.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
TrilliumBiO social profiles
Digital presenceTrilliumBiO compliance and trust
Trust signalCompliance5 records
TrilliumBiO financial estimates
Financial estimateRevenue estimate
Valuation estimate
TrilliumBiO leadership team
Management profileNumber of profiles
Profiles5 records
TrilliumBiO funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TrilliumBiO M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TrilliumBiO
What does TrilliumBiO do?
TrilliumBiO is a life sciences company that develops, validates, and commercializes diagnostic assays (Laboratory Developed Tests) through its multi-accredited, CLIA-certified, CAP-accredited, ISO 15189-accredited laboratory in Rockville, MD. It partners with biotech and pharmaceutical companies to co-develop companion diagnostics and provides biomarker discovery, assay validation, and clinical testing services to physicians and patients nationwide. Its portfolio includes specialized tests for autoimmune pulmonary alveolar proteinosis (aPAP ClearPath), alpha-1 antitrypsin deficiency (AlphaID), and uveal melanoma monitoring (Oncular), processing over 500,000 samples annually.
Is TrilliumBiO a public or private company?
TrilliumBiO is a private company. It is classified as unknown and is currently operating.
When was TrilliumBiO founded?
TrilliumBiO was founded in 2022. It employs 11 to 50 people.
Where is TrilliumBiO based?
TrilliumBiO is headquartered in Rockville, United States, in the North America region.
How does TrilliumBiO make money?
Three revenue lines are on record. Laboratory Diagnostic Testing Services are the primary driver. The others are pharmaceutical and Biotech Partnership Services and companion Diagnostic Development and Licensing.
Who are TrilliumBiO's main competitors?
Direct peers on record are NeoGenomics Laboratories, Natera, Guardant Health, BioReference Laboratories (OPKO Health), Myriad Genetics, Caris Life Sciences and Veracyte. Broad incumbents are Laboratory Corporation of America (LabCorp), Quest Diagnostics and Foundation Medicine (Roche).
Does TrilliumBiO have an API?
No public API is recorded for TrilliumBiO.
What industry is TrilliumBiO in?
TrilliumBiO's product category is Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAFAMAB, Clinical Chemistry & Immunoassay Laboratories. Its NAICS code is 62151 and its SIC code is 8071.